[go: up one dir, main page]

AU2001263114A1 - Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci - Google Patents

Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci

Info

Publication number
AU2001263114A1
AU2001263114A1 AU2001263114A AU6311401A AU2001263114A1 AU 2001263114 A1 AU2001263114 A1 AU 2001263114A1 AU 2001263114 A AU2001263114 A AU 2001263114A AU 6311401 A AU6311401 A AU 6311401A AU 2001263114 A1 AU2001263114 A1 AU 2001263114A1
Authority
AU
Australia
Prior art keywords
taci
april
bcma
agp
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001263114A
Inventor
Lars Eyde Theill
Gang Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AU2001263114A1 publication Critical patent/AU2001263114A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

This invention concerns interactions among APRIL/G70, AGP-3/BLYS, BCMA, and TACI and related methods of use and compositions of matter. It has been found that (1) sAPRIL/G70 binds to the cell-surface receptors BCMA and TACI on T and B lymphoma cells, resulting in stimulation of proliferation of primary human and mouse B and T cells both in vitro and in vivo; (2) APRIL competes with AGP3's binding to TACI and BCMA; (3) sBCMA inhibits APRIL and AGP3 binding to its receptors; (4) sBCMA ameliorates T cell dependent and T cell independent humoral immune responses in vivo; (5) sTACI inhibits APRIL and AGP3 binding to its receptors and ameliorates T cell dependent and T cell independent humoral immune responses in vivo; and (6) BCMA exhibits similarity with TACI within a single cysteine rich domain located N-terminal to a potential transmembrane domain. These discoveries provides a strategy for development of therapeutics for treatment of autoimmune diseases, and cancer, for prevention of transplant rejection. Disease states and disease parameters associated with APRIL and AGP-3 may be affected by modulation of BCMA or TACI; disease states and parameters associated with TACI can be affected by modulation of APRIL; disease states and parameters can be affected by modulation of any of TACI, BCMA, APRIL and AGP-3 by a single therapeutic agent or two or more therapeutic agents together.
AU2001263114A 2000-05-12 2001-05-14 Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci Abandoned AU2001263114A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
USNOTGIVEN 1997-05-02
US20403900P 2000-05-12 2000-05-12
US60204039 2000-05-12
US21459100P 2000-06-27 2000-06-27
US60214591 2000-06-27
PCT/US2001/015567 WO2001087979A2 (en) 2000-05-12 2001-05-14 Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci

Publications (1)

Publication Number Publication Date
AU2001263114A1 true AU2001263114A1 (en) 2001-11-26

Family

ID=26899121

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2001261557A Ceased AU2001261557B2 (en) 2000-05-12 2001-05-14 Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
AU6155701A Pending AU6155701A (en) 2000-05-12 2001-05-14 Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
AU2001263114A Abandoned AU2001263114A1 (en) 2000-05-12 2001-05-14 Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AU2001261557A Ceased AU2001261557B2 (en) 2000-05-12 2001-05-14 Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
AU6155701A Pending AU6155701A (en) 2000-05-12 2001-05-14 Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci

Country Status (10)

Country Link
US (2) US6774106B2 (en)
EP (1) EP1280826B1 (en)
JP (1) JP2003533218A (en)
AT (1) ATE361318T1 (en)
AU (3) AU2001261557B2 (en)
CA (1) CA2408617A1 (en)
DE (1) DE60128216T2 (en)
ES (1) ES2287130T3 (en)
MX (1) MXPA02011130A (en)
WO (2) WO2001087977A2 (en)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
US7217788B2 (en) 1996-03-14 2007-05-15 Human Genome Sciences, Inc. Human tumor necrosis factor delta polypeptides
US6812327B1 (en) * 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US8212004B2 (en) * 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
KR20090016772A (en) 1999-08-17 2009-02-17 바이오겐 아이덱 엠에이 인코포레이티드 BAF receptor (UCMA), immunomodulator
UA74798C2 (en) * 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Method for treating cancer in mammals using polypeptide interfering with interaction between april and its receptors
DK1666052T3 (en) * 2000-02-16 2011-09-12 Genentech Inc Anti-APRIL monoclonal antibody and its use in the treatment of an immune-related disease or cancer
US20040013674A1 (en) * 2001-04-27 2004-01-22 Christine Ambrose Taci as an anti-tumor agent
US7371388B1 (en) 2000-05-04 2008-05-13 Human Genome Sciences, Inc. Treatment of Sjogren's syndrome by administration of TR18 polypeptides
US7879328B2 (en) * 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
US7138501B2 (en) 2000-06-16 2006-11-21 Human Genome Sciences, Inc. Antibodies that immunospecifically bind BLyS
EP2270040A3 (en) * 2000-08-18 2011-07-06 Human Genome Sciences, Inc. Binding polypeptides for B lymphocyte stimulator protein (BLyS)
WO2002016411A2 (en) 2000-08-18 2002-02-28 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
WO2002046231A2 (en) * 2000-12-07 2002-06-13 The University Of British Columbia Caml-binding peptides
AU2002238052A1 (en) * 2001-02-20 2002-09-04 Zymogenetics, Inc. Antibodies that bind both bcma and taci
BRPI0209933B8 (en) 2001-05-24 2021-05-25 Zymogenetics Inc fusion protein, and, nucleic acid molecule
EP1401870A4 (en) 2001-05-24 2006-04-19 Human Genome Sciences Antibodies against tumor necrosis factor delta (april)
IL160127A0 (en) * 2001-08-03 2004-06-20 Genentech Inc Tacis and br3 polypeptides and uses thereof
AU2002364954A1 (en) * 2001-11-16 2003-07-15 Human Genome Sciences, Inc. ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS
JP2005533863A (en) * 2002-07-25 2005-11-10 ジェネンテック・インコーポレーテッド TACI antibodies and their uses
EP1558278B1 (en) * 2002-10-11 2009-09-02 ZymoGenetics, Inc. Production of homotrimeric fusion proteins
JP2006517191A (en) 2002-12-30 2006-07-20 アムジエン・インコーポレーテツド Combination therapy using costimulatory factors
EP2272868B1 (en) * 2003-06-05 2015-03-04 Genentech, Inc. Combination therapy for B cell disorders
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
US20050118728A1 (en) * 2003-07-02 2005-06-02 Caldwell Kevin K. Two-layer antibody capture system
JP2008505607A (en) * 2004-01-29 2008-02-28 ジェネンテック・インコーポレーテッド BCMA extracellular domain variants and methods of use thereof
US20080181886A1 (en) * 2004-11-04 2008-07-31 Genentech, Inc. Polypeptides That Bind Baff And/Or April
US7947805B2 (en) 2004-12-23 2011-05-24 Merck Serono S.A. BCMA polypeptides and uses thereof
JP5118037B2 (en) 2005-08-09 2013-01-16 ザイモジェネティクス， インコーポレイテッド Methods for the treatment and prevention of abnormal cell proliferation using TACI fusion molecules
MX2008001661A (en) 2005-08-09 2008-04-07 Ares Trading Sa Methods for treating b-cell malignancies using taci-ig fusion molecule.
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
KR20080074120A (en) * 2005-10-13 2008-08-12 휴먼 게놈 사이언시즈, 인코포레이티드 Methods and compositions for use in treatment of patients with autoantibody positive diseases
WO2007062090A2 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
MX2008014365A (en) 2006-05-15 2008-11-27 Ares Trading Sa Methods for treating autoimmune diseases using a taci-ig fusion molecule.
JP2010501623A (en) * 2006-08-28 2010-01-21 アレス トレーディング ソシエテ アノニム Purification method of Fc-containing protein
CN101541825B (en) * 2006-08-28 2013-08-14 阿雷斯贸易股份有限公司 Process for the purification of Fc-fusion proteins
WO2008088422A2 (en) * 2006-10-25 2008-07-24 Amgen Inc. Toxin peptide therapeutic agents
HUE030134T2 (en) 2007-10-16 2017-04-28 Zymogenetics Inc Combination of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and anti-CD20 agents for treatment of autoimmune disease
WO2009062960A1 (en) * 2007-11-12 2009-05-22 Ares Trading S.A. Formulations for taci-immunoglobulin fusion proteins
WO2009132058A2 (en) 2008-04-25 2009-10-29 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
EP2396035A4 (en) * 2009-02-12 2012-09-12 Human Genome Sciences Inc USE OF ANTAGONISTS OF THE B-LYMPHOCYTE STIMULATOR PROTEIN TO PROMOTE TRANSPLANT TOLERANCE
PL2403528T3 (en) * 2009-03-02 2017-08-31 Aduro Biotech Holdings, Europe B.V. Antibodies against a proliferating inducing ligand (april)
EP2473637B1 (en) 2009-09-03 2017-03-29 F. Hoffmann-La Roche AG Methods for treating, diagnosing, and monitoring rheumatoid arthritis
WO2011109280A1 (en) 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders
ES2712102T3 (en) * 2010-09-10 2019-05-09 Tigenix S A U Means and methods of stem cell culture
US20130273055A1 (en) * 2010-11-16 2013-10-17 Eric Borges Agents and methods for treating diseases that correlate with bcma expression
RU2013140975A (en) 2011-02-28 2015-04-10 Дженентек, Инк. BIOLOGICAL MARKERS AND METHODS FOR PREDICTING SUSCEPTIBILITY TO B-CELL ANTAGONISTS
TWI679212B (en) * 2011-11-15 2019-12-11 美商安進股份有限公司 Binding molecules for e3 of bcma and cd3
AR095374A1 (en) 2013-03-15 2015-10-14 Amgen Res Munich Gmbh UNION MOLECULES FOR BCMA AND CD3
NL2011406C2 (en) * 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
MX379210B (en) 2014-02-07 2025-03-10 Univ Mcmaster Trifunctional t cell-antigen coupler and methods and uses thereof
WO2016003876A1 (en) 2014-07-03 2016-01-07 Oklahoma Medical Research Foundation Treatment of multiple sclerosis and neuromyelitis optica
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
IL274151B (en) 2015-05-21 2022-07-01 Harpoon Therapeutics Inc Trispecific binding proteins and methods of use
IL313508A (en) 2015-11-25 2024-08-01 Visterra Inc Antibody molecules to APRIL and uses thereof
CN119060177A (en) 2016-05-20 2024-12-03 哈普恩治疗公司 Single domain serum albumin binding protein
JP7432363B2 (en) 2016-06-21 2024-02-16 テネオバイオ， インコーポレイテッド CD3 binding antibody
CR20220408A (en) 2016-09-14 2022-10-20 Teneobio Inc Cd3 binding antibodies
BR112019012354A2 (en) 2016-12-21 2019-11-26 Teneobio Inc anti-bcma heavy chain antibodies only
IL271194B2 (en) 2017-06-20 2024-10-01 Teneobio Inc Anti-BCMA antibodies containing only heavy chains
CN110945030A (en) * 2017-06-20 2020-03-31 丹娜法伯癌症研究院 Methods of Modulating Regulatory T Cells, Regulatory B Cells, and Immune Responses Using Modulators of APRIL-TACI Interactions
WO2019046818A1 (en) * 2017-09-01 2019-03-07 Dana-Farber Cancer Institute, Inc. Immunogenic peptides specific to bcma and taci antigens for treatment of cancer
US11643472B2 (en) 2017-10-12 2023-05-09 Mcmaster University T cell-antigen coupler with Y182T mutation and methods and uses thereof
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B cell maturation antigen binding proteins
EP3694529B1 (en) 2017-10-13 2024-06-26 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
IL317554A (en) 2018-06-01 2025-02-01 Novartis Ag Binding molecules against bcma and uses thereof
US11110123B2 (en) 2018-07-17 2021-09-07 Triumvira Immunologics Usa, Inc. T cell-antigen coupler with various construct optimizations
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
WO2020069028A1 (en) 2018-09-25 2020-04-02 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
EA202192736A1 (en) 2019-04-05 2022-01-27 Тенеобио, Инк. ANTIBODIES CONTAINING ONLY HEAVY CHAINS THAT BIND TO PSMA
CN121293351A (en) 2019-05-21 2026-01-09 诺华股份有限公司 CD19 binding molecules and uses thereof
BR112021024956A2 (en) 2019-06-14 2022-01-25 Teneobio Inc Multispecific heavy chain antibodies that bind cd22 and cd3
CN112979807B (en) * 2019-12-17 2022-07-26 深圳市菲鹏生物治疗股份有限公司 BCMA binding antibodies and uses thereof
US20230203161A1 (en) 2020-04-29 2023-06-29 Teneobio, Inc Multispecific heavy chain antibodies with modified heavy chain constant regions
AU2021267276B2 (en) 2020-05-08 2024-10-24 Alpine Immune Sciences, Inc. APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof
KR20240037892A (en) 2021-06-01 2024-03-22 트리움비라 이뮤놀로직스 유에스에이, 인크. Claudin 18.2 T cell-antigen coupler and uses thereof
US11453723B1 (en) 2021-06-25 2022-09-27 Mcmaster University BCMA T cell-antigen couplers and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4289872A (en) * 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
JPH07505915A (en) 1992-04-14 1995-06-29 コーネル　リサーチ　ファウンデーション、インコーポレーテッド Dendritic macromolecules and their production method
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
EP0904107B1 (en) 1996-03-18 2004-10-20 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
CA2266439C (en) 1996-10-25 2009-06-16 Human Genome Sciences, Inc. Neutrokine .alpha.
WO1998027114A2 (en) 1996-12-17 1998-06-25 Schering Corporation Mammalian cell surface antigens; related reagents
US5969102A (en) * 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
CA2232743A1 (en) 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5
IL133315A0 (en) 1997-06-06 2001-04-30 Regeneron Pharma Ntn-2 member of tnf ligand family
CA2292899A1 (en) 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
US6171787B1 (en) 1997-06-26 2001-01-09 Abbott Laboratories Member of the TNF family useful for treatment and diagnosis of disease
WO1999011791A2 (en) 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
IL134537A0 (en) 1997-09-12 2001-04-30 Apotech Sa Nucleic acid encoding an april ligand or a fragment thereof, vectors and host cells containing the same and methods for the production thereof
IL134480A0 (en) 1997-09-12 2001-04-30 Apotech Sa Kay - an immune system protein and dna sequences encoding the same
US6297022B1 (en) 1997-10-08 2001-10-02 Smithkline Beecham Corporation Method of identifying agonists and antagonists for tumor necrosis related receptor TR1
WO1999026976A1 (en) 1997-11-26 1999-06-03 Eli Lilly And Company Tnf ligand family gene
AU736506B2 (en) 1997-12-03 2001-07-26 Genentech Inc. Polypeptides and nucleic acids encoding the same
WO1999033980A2 (en) 1997-12-30 1999-07-08 Chiron Corporation Members of tnf and tnfr families
AU2212299A (en) 1998-01-05 1999-07-26 Genentech Inc. Compositions and methods for the treatment of tumor
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
CN101518648A (en) * 1999-01-07 2009-09-02 津莫吉尼蒂克斯公司 Soluble receptor BR43x2 and methods of using
US6475987B1 (en) * 1999-05-06 2002-11-05 National Jewish Medical And Research Center Tall-1 receptor homologues
KR20090016772A (en) * 1999-08-17 2009-02-17 바이오겐 아이덱 엠에이 인코포레이티드 BAF receptor (UCMA), immunomodulator
UA74798C2 (en) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Method for treating cancer in mammals using polypeptide interfering with interaction between april and its receptors
DK1666052T3 (en) * 2000-02-16 2011-09-12 Genentech Inc Anti-APRIL monoclonal antibody and its use in the treatment of an immune-related disease or cancer

Also Published As

Publication number Publication date
US6774106B2 (en) 2004-08-10
JP2003533218A (en) 2003-11-11
WO2001087977A2 (en) 2001-11-22
MXPA02011130A (en) 2003-03-10
AU2001261557B2 (en) 2005-06-30
AU6155701A (en) 2001-11-26
EP1280826B1 (en) 2007-05-02
WO2001087979A2 (en) 2001-11-22
WO2001087977A3 (en) 2002-06-20
EP1280826A2 (en) 2003-02-05
US20020081296A1 (en) 2002-06-27
US20020086018A1 (en) 2002-07-04
ES2287130T3 (en) 2007-12-16
CA2408617A1 (en) 2001-11-22
DE60128216D1 (en) 2007-06-14
DE60128216T2 (en) 2008-01-10
ATE361318T1 (en) 2007-05-15
WO2001087979A3 (en) 2002-05-30

Similar Documents

Publication Publication Date Title
AU2001263114A1 (en) Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
EA200501810A1 (en) COMPOSITION OF CONJUGATED MEDICINE
IL197550A0 (en) Inhibitors of bruton's tyrosine kinase
PT1742644E (en) Therapeutic compositions containing at least one pyrrolobenzodiazepine derivative and fludarabine
DK1407017T3 (en) Human receptor for tumor nekrose faktor
EP2172246A3 (en) Methods for Alzheimer's disease treatment and cognitive enhancement
DE60233720D1 (en) KAPPA OPIOID RECEPTOR LIGANDS
DK0839026T3 (en) Micellar polyether block copolymer compositions for targeting biological agents
WO2005097219A3 (en) Ecm-based graft material
PT1053256E (en) Antibodies to death receptor 4 (dr4) and uses thereof
NZ592973A (en) Compositions and methods of using angiopoietin-like 4 protein
TW200735890A (en) Compositions and methods for increasing insulin sensitivity
WO2003066661A3 (en) Human dr4 antibodies and uses thereof
ATE413179T1 (en) THERAPEUTIC USES OF STEROIDS IN BLOOD CELL DEFICIENCY CONDITIONS
WO2004031129A3 (en) Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
ATE543491T1 (en) COMBINATION PREPARATION CONTAINING IBUPROFEN AND PARACETAMOL
IL171974A0 (en) Tetrahydrocarbazole derivatives and their pharmaceutical use
WO2000078327A3 (en) Agents for treating malignant diseases using e1a-deficient adenoviruses with yb-1 protein-dependent replication
GB0102145D0 (en) Substances
MXPA02005069A (en) Tr3 specific binding agents and methods for their use.
IL171384A (en) Use of slurp-1 in the preparation of medicaments for the treatment of neurological disorders
UA86802C2 (en) Combination of simethicone and bisacodyl for constipated patients suffering from bloated feeling
WO1999045103A3 (en) Human spinal cord cell lines and methods of use therefor
ID23184A (en) SALES OF BPC PEPTIDES WITH ORGANOPROTECTIVE ACTIVITIES FOR THE PROCESS OF MAKING AND USING IT IN THERAPY
WO2005001053A3 (en) Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular antagonist